Oncosil Medical
Main menu
  • Logo on scroll
  • Home
  • About
    • Company History
    • Leadership Team
    • Our Board
  • Research & Technology
    • Overview
    • Chemotherapy & OncoSil™
    • Indications
    • OncoSil™ Implant
    • Implant Aftercare
    • Radiation Safety Aspects
    • About Clinical Trials
    • Clinical Studies
    • Becoming an OncoSil™ Trial Centre
    • Important Risk Information
    • FAQ
  • Investor Centre
    • Overview
    • ASX Announcements
    • Analyst Reports
    • Annual Reports
    • Events & Presentations
    • Subscribe to Updates
    • Corporate Governance
  • Media Coverage
  • Contact Us

Notice: OncosilTM is currently unapproved in all jurisdictions

Transforming the prognosis

Transforming the prognosis

Lead
Product

OncoSilTM is a brachytherapy device that implants a pre-determined dose of beta radiation. The beta particles emitted by OncoSilTM travel a short distance in tissue causing damage to targeted cell DNA, which renders them incapable of further cell division and proliferation.

OncoSil Medical is currently undertaking clinical studies to investigate the clinical benefit of the addition of OncoSilTM when combined with standard of care chemotherapies in the pancreas.

Platform Technology

OncoSil Medical Ltd has developed a new technology - Phosphorous-32 Microparticles suspended in Diluent.

This product is called OncoSilTM and is an active implantable (radiological) medical device injected during an Endoscopic Ultrasound (EUS) guidance procedure.

COMPANY
OVERVIEW

Oncosil Medical is a Sydney based  medical device company focused on Interventional Oncology in the pancreas and liver. Oncosil Medical has developed a medical device called OncosilTM and is progressing towards product commercialisation.

The device is currently undergoing clinical studies globally. The clinical data will be used for regulatory submissions in the EU, USA, Australia and Asia.


Research and

Research and

Technology

Investors

Investors

Centre

Clinical

Clinical

Studies

Becoming an Oncosil

Becoming an Oncosil

Trial Centre

Investor News

Oncosil Video

Watch video

Investor Call Q2, FY18

Listen: Conference Call

 

Media Coverage

 

Clinical Update and CEO Interview

 


Sky News

Interview with Dr Chris Roberts, Sky News May 5, 2017.

Channel 9 News

Channel 9 News media article - Monash Medical Centre.

WIN News

WIN News media article

Get in touch

Subscribe to updates

Oncosil Medical Ltd,
Suite 402, Level 4 50 Berry Street,
North Sydney, NSW 2060
+61 2 9223 3344
info@oncosil.com.au
Footer
  • Disclaimer
  • Copyright ©2017 Oncosil Medical Ltd
  • Designed & Powered by Web Force 5